PMC:7200337 / 46164-46982 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T459","span":{"begin":18,"end":21},"obj":"Body_part"},{"id":"T460","span":{"begin":32,"end":37},"obj":"Body_part"},{"id":"T461","span":{"begin":50,"end":54},"obj":"Body_part"},{"id":"T462","span":{"begin":181,"end":189},"obj":"Body_part"},{"id":"T463","span":{"begin":190,"end":194},"obj":"Body_part"},{"id":"T464","span":{"begin":711,"end":719},"obj":"Body_part"}],"attributes":[{"id":"A459","pred":"fma_id","subj":"T459","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A460","pred":"fma_id","subj":"T460","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A461","pred":"fma_id","subj":"T461","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A462","pred":"fma_id","subj":"T462","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A463","pred":"fma_id","subj":"T463","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A464","pred":"fma_id","subj":"T464","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"RBD-specific CD19+IgG+ memory B cells were single-cell sorted from a cohort of eight COVID-19 donors between days 9 and 28 after the onset of symptoms (Ju et al., 2020). From their antibody gene sequences, 209 SARS-CoV-2-specific monoclonal antibodies were produced. The monoclonal antibodies had a diverse repertoire, relatively low or no somatic mutations, and variable binding reactivity, with dissociation constants reaching 10−8 to 10−9, similar to antibodies isolated during acute infections. Two potent neutralizing SARS-CoV-2 RBD-specific monoclonal antibodies were characterized that did not crossreact with the RBD of SARS-CoV-1 or MERS-CoV (Ju et al., 2020). Together, these results demonstrate that antibody mediated neutralization is virus specific and likely driven by binding of epitopes within the RBD."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T293","span":{"begin":85,"end":93},"obj":"Disease"},{"id":"T294","span":{"begin":210,"end":218},"obj":"Disease"},{"id":"T295","span":{"begin":487,"end":497},"obj":"Disease"},{"id":"T296","span":{"begin":523,"end":531},"obj":"Disease"},{"id":"T297","span":{"begin":628,"end":636},"obj":"Disease"}],"attributes":[{"id":"A293","pred":"mondo_id","subj":"T293","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A294","pred":"mondo_id","subj":"T294","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A295","pred":"mondo_id","subj":"T295","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A296","pred":"mondo_id","subj":"T296","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A297","pred":"mondo_id","subj":"T297","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"RBD-specific CD19+IgG+ memory B cells were single-cell sorted from a cohort of eight COVID-19 donors between days 9 and 28 after the onset of symptoms (Ju et al., 2020). From their antibody gene sequences, 209 SARS-CoV-2-specific monoclonal antibodies were produced. The monoclonal antibodies had a diverse repertoire, relatively low or no somatic mutations, and variable binding reactivity, with dissociation constants reaching 10−8 to 10−9, similar to antibodies isolated during acute infections. Two potent neutralizing SARS-CoV-2 RBD-specific monoclonal antibodies were characterized that did not crossreact with the RBD of SARS-CoV-1 or MERS-CoV (Ju et al., 2020). Together, these results demonstrate that antibody mediated neutralization is virus specific and likely driven by binding of epitopes within the RBD."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T578","span":{"begin":13,"end":17},"obj":"http://purl.obolibrary.org/obo/CLO_0053432"},{"id":"T579","span":{"begin":30,"end":37},"obj":"http://purl.obolibrary.org/obo/CL_0000236"},{"id":"T580","span":{"begin":50,"end":54},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T581","span":{"begin":67,"end":68},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T582","span":{"begin":190,"end":194},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T583","span":{"begin":297,"end":298},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T584","span":{"begin":747,"end":752},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"RBD-specific CD19+IgG+ memory B cells were single-cell sorted from a cohort of eight COVID-19 donors between days 9 and 28 after the onset of symptoms (Ju et al., 2020). From their antibody gene sequences, 209 SARS-CoV-2-specific monoclonal antibodies were produced. The monoclonal antibodies had a diverse repertoire, relatively low or no somatic mutations, and variable binding reactivity, with dissociation constants reaching 10−8 to 10−9, similar to antibodies isolated during acute infections. Two potent neutralizing SARS-CoV-2 RBD-specific monoclonal antibodies were characterized that did not crossreact with the RBD of SARS-CoV-1 or MERS-CoV (Ju et al., 2020). Together, these results demonstrate that antibody mediated neutralization is virus specific and likely driven by binding of epitopes within the RBD."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T145","span":{"begin":23,"end":29},"obj":"http://purl.obolibrary.org/obo/GO_0007613"},{"id":"T146","span":{"begin":711,"end":743},"obj":"http://purl.obolibrary.org/obo/GO_0097282"}],"text":"RBD-specific CD19+IgG+ memory B cells were single-cell sorted from a cohort of eight COVID-19 donors between days 9 and 28 after the onset of symptoms (Ju et al., 2020). From their antibody gene sequences, 209 SARS-CoV-2-specific monoclonal antibodies were produced. The monoclonal antibodies had a diverse repertoire, relatively low or no somatic mutations, and variable binding reactivity, with dissociation constants reaching 10−8 to 10−9, similar to antibodies isolated during acute infections. Two potent neutralizing SARS-CoV-2 RBD-specific monoclonal antibodies were characterized that did not crossreact with the RBD of SARS-CoV-1 or MERS-CoV (Ju et al., 2020). Together, these results demonstrate that antibody mediated neutralization is virus specific and likely driven by binding of epitopes within the RBD."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1538","span":{"begin":451,"end":453},"obj":"Gene"},{"id":"1539","span":{"begin":434,"end":436},"obj":"Gene"},{"id":"1540","span":{"begin":523,"end":533},"obj":"Species"},{"id":"1541","span":{"begin":628,"end":636},"obj":"Species"},{"id":"1542","span":{"begin":642,"end":650},"obj":"Species"},{"id":"1543","span":{"begin":210,"end":220},"obj":"Species"},{"id":"1544","span":{"begin":85,"end":93},"obj":"Disease"},{"id":"1545","span":{"begin":481,"end":497},"obj":"Disease"}],"attributes":[{"id":"A1538","pred":"tao:has_database_id","subj":"1538","obj":"Gene:6999"},{"id":"A1539","pred":"tao:has_database_id","subj":"1539","obj":"Gene:6999"},{"id":"A1540","pred":"tao:has_database_id","subj":"1540","obj":"Tax:2697049"},{"id":"A1541","pred":"tao:has_database_id","subj":"1541","obj":"Tax:694009"},{"id":"A1542","pred":"tao:has_database_id","subj":"1542","obj":"Tax:1335626"},{"id":"A1543","pred":"tao:has_database_id","subj":"1543","obj":"Tax:2697049"},{"id":"A1544","pred":"tao:has_database_id","subj":"1544","obj":"MESH:C000657245"},{"id":"A1545","pred":"tao:has_database_id","subj":"1545","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"RBD-specific CD19+IgG+ memory B cells were single-cell sorted from a cohort of eight COVID-19 donors between days 9 and 28 after the onset of symptoms (Ju et al., 2020). From their antibody gene sequences, 209 SARS-CoV-2-specific monoclonal antibodies were produced. The monoclonal antibodies had a diverse repertoire, relatively low or no somatic mutations, and variable binding reactivity, with dissociation constants reaching 10−8 to 10−9, similar to antibodies isolated during acute infections. Two potent neutralizing SARS-CoV-2 RBD-specific monoclonal antibodies were characterized that did not crossreact with the RBD of SARS-CoV-1 or MERS-CoV (Ju et al., 2020). Together, these results demonstrate that antibody mediated neutralization is virus specific and likely driven by binding of epitopes within the RBD."}

{"project":"LitCovid-sentences","denotations":[{"id":"T250","span":{"begin":0,"end":169},"obj":"Sentence"},{"id":"T251","span":{"begin":170,"end":266},"obj":"Sentence"},{"id":"T252","span":{"begin":267,"end":498},"obj":"Sentence"},{"id":"T253","span":{"begin":499,"end":669},"obj":"Sentence"},{"id":"T254","span":{"begin":670,"end":818},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"RBD-specific CD19+IgG+ memory B cells were single-cell sorted from a cohort of eight COVID-19 donors between days 9 and 28 after the onset of symptoms (Ju et al., 2020). From their antibody gene sequences, 209 SARS-CoV-2-specific monoclonal antibodies were produced. The monoclonal antibodies had a diverse repertoire, relatively low or no somatic mutations, and variable binding reactivity, with dissociation constants reaching 10−8 to 10−9, similar to antibodies isolated during acute infections. Two potent neutralizing SARS-CoV-2 RBD-specific monoclonal antibodies were characterized that did not crossreact with the RBD of SARS-CoV-1 or MERS-CoV (Ju et al., 2020). Together, these results demonstrate that antibody mediated neutralization is virus specific and likely driven by binding of epitopes within the RBD."}